C14orf166 Is a Biomarker for Predicting Hepatocellular Carcinoma Recurrence

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34–42. doi:10.1038/nrgastro.2012.199.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943. doi:10.1016/j.jhep.2011.12.001.
   PubMed Web of Science ®Google Scholar
• Wang N-Y, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev. 2014;15(4):1539–1544. doi:10.7314/APJCP.2014.15.4.1539.
   PubMedGoogle Scholar
• Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44(9):991–999. doi:10.1007/s00535-009-0093-z.
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/S0168-8278(02)00360-4.
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–235. doi:10.1097/01.sla.0000197706.21803.a1.
   PubMed Web of Science ®Google Scholar
• Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141(3):330–339. doi:10.1016/j.surg.2006.06.028.
   PubMed Web of Science ®Google Scholar
• Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection . J Am Med Assoc. 2012;308(18):1906–1914.
   PubMed Web of Science ®Google Scholar
• Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–897. doi:10.1016/j.jhep.2009.07.009.
   PubMed Web of Science ®Google Scholar
• Kakazu E, Kondo Y, Kogure T, et al. Supplementation of branched-chain amino acids maintains the serum albumin level in the course of hepatocellular carcinoma recurrence. Tohoku J Exp Med. 2013;230(4):191–196.
   PubMed Web of Science ®Google Scholar
• Huarte M, Sanz-Ezquerro JJ, Roncal F, Ortin J, Nieto A. PA subunit from influenza virus polymerase complex interacts with a cellular protein with homology to a family of transcriptional activators. J Virol. 2001;75(18):8597–8604.
   PubMed Web of Science ®Google Scholar
• Lee JW, Liao PC, Young KC, et al. Identification of hnRNPH1, NF45, and C14orf166 as novel host interacting partners of the mature hepatitis C virus core protein. J Proteome Res. 2011;10(10):4522–4534. doi:10.1021/pr200338d.
   PubMed Web of Science ®Google Scholar
• Perez-Gonzalez A, Pazo A, Navajas R, et al. hCLE/C14orf166 associates with DDX1-HSPC117-FAM98B in a novel transcription-dependent shuttling RNA-transporting complex. PloS One. 2014;9:e90957. doi:10.1371/journal.pone.0090957.
   PubMed Web of Science ®Google Scholar
• Cui Y, Wu J, Zong M, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009;124(7):1614–1621. doi:10.1002/ijc.24163.
   PubMed Web of Science ®Google Scholar
• Guo J, Wang W, Liao P, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009;100(12):2292–2301. doi:10.1111/j.1349-7006.2009.01324.x.
   PubMed Web of Science ®Google Scholar
• Howng SL, Hsu HC, Cheng TS, et al. A novel ninein-interaction protein, CGI-99, blocks ninein phosphorylation by GSK3beta and is highly expressed in brain tumors. FEBS Lett. 2004;566(1–3):162–168. doi:10.1016/j.febslet.2004.04.024.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ou J, Lei F, et al. C14ORF166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer. Tumor Biol. 2016;37(1):369–379. doi:10.1007/s13277-015-3806-3.
   PubMedGoogle Scholar
• Yang L, Li F, Lei F, et al. Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in human NPC. Tumor Biol. 2015;36(10):7977–7986. doi:10.1007/s13277-015-3518-8.
   PubMedGoogle Scholar
• Cheang TY, Zhou HY, Chen W, et al. C14orf166 overexpression correlates with tumor progression and poor prognosis of breast cancer. J Transl Med. 2016;14:54. doi:10.1186/s12967-016-0805-0.
   PubMed Web of Science ®Google Scholar
• Chen M, Ye Y, Zou B, et al. C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation. J Transl Med. 2016;14:55. doi:10.1186/s12967-016-0801-4.
   PubMed Web of Science ®Google Scholar
• Zhou YW, Li R, Duan CJ, et al. Expression and clinical significance of C14orf166 in esophageal squamous cell carcinoma. Mol Med Rep. 2017;15(2):605–612. doi:10.3892/mmr.2016.6056.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union against Cancer and the American Joint Committee on Cancer. Cancer 2010;116(22):5336–5339. doi:10.1002/cncr.25537.
   PubMed Web of Science ®Google Scholar
• Sena P, Roncucci L, Marzona L, et al. Altered expression of apoptosis biomarkers in human colorectal microadenomas. Cancer Epidemiol Biomarkers Prev. 2010;19:351–357. doi:10.1158/1055-9965.EPI-09-0438.
   PubMed Web of Science ®Google Scholar
• Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–2620. doi:10.1002/art.38690.
   PubMed Web of Science ®Google Scholar
• Weng S, Wang H, Chen W, et al. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012;21:1336–1343. doi:10.1158/1055-9965.EPI-12-0223.
   PubMed Web of Science ®Google Scholar
• Cheng L-S, Tu W-J, Shen Y, Zhang L-J, Ji K. Combination of high-sensitivity C-reactive protein and homocysteine predicts the post-stroke depression in patients with ischemic stroke. Mol Neurobiol. 2017;55(4):2952–2958. doi:10.1007/s12035-017-0549-8.
   Web of Science ®Google Scholar
• Qin T, Liu H, Song Q, et al. The screening of volatile markers for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19:2247–2253. doi:10.1158/1055-9965.EPI-10-0302.
   PubMed Web of Science ®Google Scholar
• Chen X, Ying Z, Lin X, et al. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest. 2013;123(6):2576–2589. doi:10.1172/JCI68143.
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746. doi:10.1038/nrc3818.
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. doi:10.1038/nrc2734.
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97–105. doi:10.1038/nrc1275.
   PubMed Web of Science ®Google Scholar
• Dou N, Chen J, Yu S, Gao Y, Li Y. G3BP1 contributes to tumor metastasis via upregulation of Slug expression in hepatocellular carcinoma. Am J Cancer Res. 2016;6(11):2641–2650.
   Web of Science ®Google Scholar
• Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–328. doi:10.1097/01.sla.0000201480.65519.b8.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–912. doi:10.1097/SLA.0b013e3181efc656.
   PubMed Web of Science ®Google Scholar
• Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802. doi:10.1016/j.jhep.2012.05.007.
   PubMed Web of Science ®Google Scholar
• Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240(1):102–107.
   PubMed Web of Science ®Google Scholar
• Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 2006;44(6):1518–1527. doi:10.1002/hep.21408.
   PubMed Web of Science ®Google Scholar
• Nörthen A, Asendorf T, Walson PD, Oellerich M. Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. Clin Biochem. 2018;52:20–25. doi:10.1016/j.clinbiochem.2017.10.011.
   PubMed Web of Science ®Google Scholar